Literature DB >> 23437940

An equivalence test for the comparison between a test drug and placebo in human abuse potential studies.

Ling Chen1, Katherine R Bonson.   

Abstract

Statistical methodologies for human abuse potential studies are rarely evaluated. Human abuse potential studies assess whether test drugs produce positive and negative subjective responses on abuse-related measures using volunteers with histories of recreational drug use. These studies typically have a randomized, double-blind, placebo- and positive-controlled crossover design with at least four treatments: placebo, at least two doses of a test drug, and at least one dose of a positive control drug (a drug with known abuse potential). This article proposes a new test for assessing whether a test drug produces data indicative of abuse potential when compared to placebo.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23437940     DOI: 10.1080/10543406.2011.616972

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  4 in total

1.  Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.

Authors:  Sharon L Walsh; Sandra D Comer; Michelle R Lofwall; Bradley Vince; Naama Levy-Cooperman; Debra Kelsh; Marion A Coe; Jermaine D Jones; Paul A Nuzzo; Fredrik Tiberg; Behshad Sheldon; Sonnie Kim
Journal:  JAMA Psychiatry       Date:  2017-09-01       Impact factor: 21.596

2.  Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo- and Alprazolam-Controlled Crossover Study.

Authors:  Darren Wilbraham; Paul H Berg; Max Tsai; Emily Liffick; Li Shen Loo; Erin Gautier Doty; Edward Sellers
Journal:  J Clin Pharmacol       Date:  2019-11-20       Impact factor: 3.126

3.  Evaluation of the abuse potential of difelikefalin, a selective kappa-opioid receptor agonist, in recreational polydrug users.

Authors:  Megan J Shram; Robert H Spencer; Jenny Qian; Catherine L Munera; Michael E Lewis; Jack E Henningfield; Lynn Webster; Frédérique Menzaghi
Journal:  Clin Transl Sci       Date:  2021-10-28       Impact factor: 4.689

4.  Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy.

Authors:  Beatrice Setnik; Michael McDonnell; Catherine Mills; Catherine Scart-Grès; Philippe Robert; Jeffrey M Dayno; Jean-Charles Schwartz
Journal:  Sleep       Date:  2020-04-15       Impact factor: 5.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.